JNJ-

WO/2009/058801 is a use application for the pictured c-FMS inhibitor.

it’s JnJ-141 in the application, but does it have a dev #?

2I1M suggests a binding mode:

PLX-5568

Plexxikon’s Ph1 in healthy volunteers underway with plans for and pain and PKD. They’re not advertising the target, but my guess is c-fms. We’ve been following their earlier cFms / cKkit double-stuff, and its likely they found a group to tune out the Kit, maybe something like: WO/2008/080015

still no partner…

WO/2007/071955

Title’d app is from AstraZeneca and has ’bout 82 thiazoles said to hit c-Fms.

click for the guess

ABT-869

Phase 2 on the doorstep, Genentech and Abbott just announced a collaboration to include development of the compound w/ backups. No terms disclosed…

Vegf, Flt3, Tie2, c-FMS, Pdgf, c-kit yadda yadda

j med chem, blood, molec cancer ther., WO/2004/113304

Axitinib

aka AG-013736 is a Pfizer Vegf / c-FMS compound via Agouron.

Salt: Tosylate?
Clinic Ph iii: Pancreatic Cancer
WO/2001/002369; process app; ‘06 Asco,

Plexxikon’s cFms/cKit stuff:

Some of Plexxicon’s latest cKit / cFms stuff has published, and surprise-surprise its got their ’scaffold’. The choice of where to tag on amines suggests the following motif:

This week: US20070032519
Last week: WO/2007/013896
Last year: WO/2006/009797

Kinase PDB’s: c-FMS

c-FMS (CSF1R if your from Cytopia.) is on the docket this week: 2IOV, 2IOY, 2I1M These are the first cFMS published methinks?

Well consider this colony stimulated.

US20060258666

Hey Hey J & J,  Nice c-FMS inhibitors.  As kinase inhibitors go these are new to me, but I see you’ve been banging away at these for a few years so there’s got to be a candidate in there somewhere, eh?

CYT645

Tag Cytopia, I see you nominated a c-fms inhibitor, neet-0, but no patent app published yet? There’s an article in FASEB, but whats say we stick with calling it c-fms, eh? If you want to get creative, lets go with c-FMS, or fms, or maybe even CFMS, but CSF-1R? Aww c’mon, we’ve got enough names to keep up with How about a little standardization here, people?!

From application WO2004054977 it appears the cross screens for your JAK2/3 programs included c-fms, hck, zap70, fes, and abl. I like it, nice way to determine selectivity profile, and to find the serendipitous hit here and there. Good show, my guess is you found something with a little fms selectivity.

Also, I’m a little behind the times, so a belated congrats on partnering your JAK3 program with Novartis.

Tschüss